These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 2389941

  • 1. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
    Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Harada T, Ohgaki K, Tobe T.
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1421-7. PubMed ID: 2389941
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of intracavitary administration of cyclophosphamide, interleukin-2 and lymphokine activated killer cells against established intraperitoneal tumor.
    Eggermont AM, Sugarbaker PH.
    Acta Med Austriaca; 1989 Aug; 16(3-4):47-50. PubMed ID: 2609913
    [Abstract] [Full Text] [Related]

  • 3. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
    Kan N, Okino T, Nakanishi M, Sato K, Mise K, Teramura Y, Yamasaki S, Hori T, Ohgaki K, Tobe T.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
    [Abstract] [Full Text] [Related]

  • 4. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R.
    J Immunol; 1998 Dec 15; 161(12):6977-84. PubMed ID: 9862733
    [Abstract] [Full Text] [Related]

  • 5. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N, Hori T, Ohgaki K, Inamoto T, Kodama H, Tobe T.
    Gan To Kagaku Ryoho; 1986 Apr 15; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [Abstract] [Full Text] [Related]

  • 6. [Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells].
    Kikuchi Y, Oomori K, Miyauchi M, Kita T, Kuki E, Iwano I, Hirata J, Nagata I.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec 15; 41(12):1891-5. PubMed ID: 2592812
    [Abstract] [Full Text] [Related]

  • 7. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E, Ben-Aziz R, Shiloni E.
    Isr J Med Sci; 1988 Dec 15; 24(9-10):494-504. PubMed ID: 3264551
    [Abstract] [Full Text] [Related]

  • 8. [Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
    Kan N, Yamasaki S, Harada T, Satoh K, Ichinose Y, Moriguchi Y, Kodama H, Ohgaki K.
    Hum Cell; 1992 Sep 15; 5(3):236-42. PubMed ID: 1467322
    [Abstract] [Full Text] [Related]

  • 9. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
    Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R.
    Cancer Res; 1987 Nov 01; 47(21):5725-32. PubMed ID: 3499218
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun 01; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 11. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
    Ujiie T.
    Jpn J Exp Med; 1988 Apr 01; 58(2):109-14. PubMed ID: 3261814
    [Abstract] [Full Text] [Related]

  • 12. Chemotherapy subsequent to recombinant interleukin-2 immunotherapy: protocol for enhanced tumoricidal activity.
    Ades EW, McKemie CR, Wright S, Peacocke N, Pantazis C, Lockhart WL.
    Nat Immun Cell Growth Regul; 1987 Apr 01; 6(5):260-8. PubMed ID: 3502171
    [Abstract] [Full Text] [Related]

  • 13. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R, Kitagawa T, Koizumi K, Sato K, Homma M.
    J Biol Response Mod; 1989 Dec 01; 8(6):676-90. PubMed ID: 2600605
    [Abstract] [Full Text] [Related]

  • 14. [A study to increase the therapeutic effects of adoptive immunotherapy in vivo. Influence on the generation of lymphokine activated killer (LAK) cells and therapeutic effects of LAK cells with anti-tumor drug (cyclophosphamide)].
    Yoshimori K.
    Nihon Ika Daigaku Zasshi; 1992 Oct 01; 59(5):418-27. PubMed ID: 1430114
    [Abstract] [Full Text] [Related]

  • 15. IL-2/LAK cell treatment for advanced cancers with emphasis on a novel administration.
    Auber ML, DeHaven JI, Raich PC, Rogers JS, Crowell EB, Romero P, Mahin EJ, Sosnowski JT, Lamm DL.
    W V Med J; 1991 Aug 01; 87(8):344-6. PubMed ID: 1949753
    [Abstract] [Full Text] [Related]

  • 16. [Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions].
    Akimoto M, Nishihira T, Kasai M.
    Gan To Kagaku Ryoho; 1986 Apr 01; 13(4 Pt 2):1270-6. PubMed ID: 3729450
    [Abstract] [Full Text] [Related]

  • 17. [Tumoricidal biological response modifiers (BRM)].
    Niitsu Y, Kohgo Y, Watanabe N.
    Gan To Kagaku Ryoho; 1990 Aug 01; 17(8 Pt 1):1407-13. PubMed ID: 1697152
    [Abstract] [Full Text] [Related]

  • 18. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ, Shu S, Rosenberg SA.
    J Immunol; 1985 Jul 01; 135(1):646-52. PubMed ID: 3889158
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma.
    Kan N, Okino T, Nakanishi M, Sato K, Mise K, Yamasaki S, Teramura Y, Ohgaki K, Tobe T.
    Biotherapy; 1989 Jul 01; 1(3):197-206. PubMed ID: 2642023
    [Abstract] [Full Text] [Related]

  • 20. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE, Mailliard RB, Lotze MT, Barksdale EM.
    J Pediatr Surg; 2003 Mar 01; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.